2025 medical insurance reimbursement price of Olaparib targeted drug

As a PARP inhibitor targeted drug, Olaparib is mainly used to treat ovarian cancer, breast cancer, prostate cancer, pancreatic cancer and other solid tumors related to BRCA gene mutations. In our country, Lynparza has been officially approved for marketing and successfully included in the national medical insurance directory, greatly reducing the financial burden on patients. At present, the main specifications available for purchase in domestic hospital pharmacies are 150mg*56 tablets. The price of a box is about four to five thousand yuan. However, after medical insurance reimbursement, the actual payment amount will be lower. The specific cost needs to be determined according to regional policies and medical insurance reimbursement ratios.

For patients under financial pressure or long-term medication needs, in addition to purchasing original drugs through medical insurance in China, they can also choose overseas generic drugs with higher cost-effectiveness. At present, generic versions of Lynparza have been launched in the markets of Bangladesh and Laos. The price of a box of 150mg*120 tablets is about 2,000 yuan, which is more affordable than the domestic original drug. The ingredients of these generic drugs are consistent with the original drugs sold in China, and they have shown good efficacy and safety in clinical use in many countries.

It should be noted that although overseas generic drugs are affordable, due to different drug sources and channels, patients need to be particularly cautious when purchasing and choose formal and legal channels to ensure drug quality and efficacy. At the same time, it is also recommended that patients consult their attending doctor before use to confirm whether generic drugs are suitable for their condition and current treatment plan, so as to avoid affecting the therapeutic effect due to changing drugs.

In general, Lynparza will have a relatively complete medical insurance support system in 2025. For most Chinese patients, reimbursement of domestic drug purchases through medical insurance can greatly alleviate financial pressure. For patients with special economic conditions, overseas generic drugs also provide viable alternatives. During the treatment process, patients should weigh the price, efficacy and medication safety based on their own conditions, and choose the most appropriate drugs and treatment options under the guidance of a doctor.

Reference materials:https://www.lynparza.com/